Hospital
Prime Healthcare Services - Sherman Oaks, LLC
Prime Healthcare Services - Sherman Oaks, LLC was paid $5.68M by Medicaid between Jan 2018 and Dec 2024, across 125 billing codes. Its largest line is 0450, Emergency room services — 24% of everything it billed.
33Billing provider infoPRIME HEALTHCARE SERVICES - SHERMAN OAKS, LLC
SHERMAN OAKS, CA 91403
SHERMAN OAKS, CA 91403
33aNPI1750491247assigned 08/30/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$5.68M
24GClaims322,541
24DCodes billed125
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#216 of 410
Median peer was paid$6.90M
This provider vs. median0.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 51,019 | $735K | |
| 2019 | 47,126 | $990K | |
| 2020 | 37,638 | $557K | |
| 2021 | 38,324 | $736K | |
| 2022 | 45,669 | $906K | |
| 2023 | 53,409 | $945K | |
| 2024incomplete | 49,356 | $809K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0450 | Emergency room services | 24% | 41,028 | 36,768 | $1.36M |
| 0270 | 6.6% | 32,869 | 26,124 | $376K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 6.2% | 6,229 | 4,424 | $353K |
| 70450 | Computed tomography, head or brain; without contrast material | 5.5% | 3,659 | 3,556 | $310K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.8% | 6,324 | 5,994 | $215K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.5% | 1,558 | 1,479 | $199K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 3.4% | 4,157 | 3,594 | $192K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 3.0% | 2,475 | 2,411 | $168K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 2.7% | 3,896 | 3,283 | $153K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 2.7% | 5,777 | 4,898 | $152K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.6% | 8,714 | 7,809 | $146K |
| J3490 | Unclassified drugs | 2.3% | 13,198 | 10,604 | $130K |
113 more codes
| 0301 | 2.0% | 2,094 | $115K | |
| 99284 | Emergency room visit (serious) | 2.0% | 1,507 | $112K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.7% | 18,341 | $99K |
| Z7502 | 1.6% | 2,402 | $90K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.6% | 19,448 | $90K |
| 99199 | Unlisted special service, procedure or report | 1.5% | 1,856 | $87K |
| 71045 | Radiologic examination, chest; single view | 1.5% | 9,501 | $86K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1.5% | 4,682 | $83K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.4% | 4,308 | $81K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.4% | 5,038 | $79K |
| 72125 | Computed tomography, cervical spine; without contrast material | 1.2% | 593 | $67K |
| 80076 | 1.2% | 13,805 | $67K | |
| 99283 | Emergency room visit (moderate) | 1.2% | 1,328 | $66K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.1% | 2,139 | $63K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.0% | 1,332 | $57K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 4,175 | $51K |
| 0272 | <1% | 5,286 | $41K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,125 | $41K |
| Z7610 | <1% | 2,471 | $39K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 312 | $36K |
| 84484 | <1% | 5,917 | $35K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 508 | $32K |
| 80143 | <1% | 2,726 | $28K | |
| 0250 | <1% | 5,507 | $26K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 646 | $23K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 5,264 | $22K |
| 83690 | <1% | 5,210 | $20K | |
| 83880 | <1% | 1,139 | $16K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,041 | $16K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,694 | $16K |
| 84703 | <1% | 3,854 | $15K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,527 | $13K |
| 81001 | <1% | 7,033 | $13K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 355 | $12K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 920 | $11K |
| 85730 | <1% | 3,434 | $11K | |
| 90715 | <1% | 432 | $10K | |
| A9150 | Non-prescription drugs | <1% | 2,401 | $9K |
| 80305 | <1% | 1,065 | $9K | |
| 73564 | <1% | 500 | $8K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,206 | $8K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,433 | $7K |
| 73630 | <1% | 453 | $6K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,514 | $6K |
| 99406 | <1% | 879 | $6K | |
| 84702 | <1% | 724 | $6K | |
| 73610 | <1% | 379 | $6K | |
| 80299 | <1% | 439 | $5K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 454 | $5K |
| 73030 | <1% | 306 | $4K | |
| 80053 | Comprehensive metabolic panel | <1% | 741 | $4K |
| 93971 | <1% | 64 | $4K | |
| 81000 | <1% | 2,149 | $3K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 689 | $3K |
| 73130 | <1% | 216 | $3K | |
| 83605 | <1% | 545 | $3K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 752 | $3K |
| A4606 | Oxygen probe for use with oximeter device, replacement | <1% | 72 | $3K |
| 87077 | <1% | 599 | $3K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 871 | $2K |
| 86403 | <1% | 343 | $2K | |
| 87186 | <1% | 526 | $2K | |
| 81003 | <1% | 1,721 | $2K | |
| 98960 | <1% | 92 | $2K | |
| 87040 | <1% | 429 | $2K | |
| A4649 | Surgical supply; miscellaneous | <1% | 2,629 | $2K |
| 82962 | <1% | 1,614 | $2K | |
| 87070 | <1% | 338 | $2K | |
| 0510 | <1% | 472 | $2K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 546 | $2K |
| 70486 | <1% | 26 | $2K | |
| 0259 | <1% | 491 | $2K | |
| 72131 | <1% | 13 | $1K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 401 | $1K |
| 0320 | <1% | 105 | $1K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 202 | $1K |
| 87400 | <1% | 201 | $1K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 156 | $1K |
| 36415 | Collection of venous blood by venipuncture | <1% | 3,614 | $1K |
| 96376 | <1% | 105 | $1K | |
| 83735 | <1% | 243 | $755.19 | |
| 73110 | <1% | 54 | $738.07 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 52 | $693.79 |
| 29125 | <1% | 73 | $668.28 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 205 | $639.21 |
| 85378 | <1% | 156 | $624.29 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 39 | $544.46 |
| 71046 | Radiologic examination, chest; 2 views | <1% | 43 | $418.02 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 112 | $417.40 |
| J3590 | Unclassified biologics | <1% | 88 | $379.22 |
| 87420 | <1% | 73 | $345.45 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 106 | $332.59 |
| 0761 | <1% | 46 | $323.08 | |
| 85007 | <1% | 198 | $265.84 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 128 | $249.46 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 82 | $232.19 |
| 0300 | <1% | 25 | $135.66 | |
| 0760 | <1% | 31 | $129.49 | |
| 80329 | <1% | 35 | $102.90 | |
| 87081 | <1% | 26 | $101.63 | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 36 | $84.99 |
| 0636 | <1% | 28 | $79.70 | |
| 86850 | <1% | 24 | $68.20 | |
| A6403 | Gauze, non-impregnated, sterile, pad size more than 16 sq. in. less than or equal to 48 sq. in., without adhesive border, each dressing | <1% | 30 | $58.77 |
| A6402 | Gauze, non-impregnated, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing | <1% | 56 | $42.20 |
| 80061 | Lipid panel | <1% | 12 | $23.08 |
| 85652 | <1% | 27 | $19.22 | |
| 86140 | <1% | 12 | $8.28 | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 13 | $7.92 |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 17 | $1.33 |
| S9445 | Patient education, not otherwise classified, non-physician provider, individual, per session | 0% | 2,133 | $0.00 |
| 0258 | 0% | 14 | $0.00 | |
| 99072 | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialREDDY, PREM (CHAIRMAN/PRES/CEO)
| Provider | Location | Paid |
|---|---|---|
| Prime Healthcare Services Mesquite LLC | Mesquite, TX | $6.58M |
| Prime Healthcare LA Palma, LLC | La Palma, CA | $3.02M |
| Paradise Valley Medical Group, INC. | National City, CA | $2.50M |
| Ohio Valley Home Care, LLC | East Liverpool, OH | $196K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.